Capital World Investors Trims Regeneron Stake to 4.7%

Ticker: REGN · Form: SC 13G/A · Filed: 2024-02-09T00:00:00.000Z

Sentiment: neutral

Topics: institutional-ownership, amendment, stake-change

TL;DR

**Capital World Investors slightly cut its Regeneron stake to 4.7%.**

AI Summary

Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing a slight decrease in its beneficial ownership of Regeneron Pharmaceuticals, Inc. common stock. As of December 29, 2023, Capital World Investors now beneficially owns 5,194,729 shares, representing 4.7% of the company's outstanding common stock. This is a minor reduction from their previous holding, indicating a slight shift in their investment strategy for Regeneron.

Why It Matters

This filing shows a significant institutional investor slightly reduced its stake in Regeneron, which could signal a minor change in their outlook on the company's future performance or valuation.

Risk Assessment

Risk Level: low — The change in ownership is minor and doesn't suggest a major shift in the company's fundamentals or a significant loss of investor confidence.

Analyst Insight

Investors should note that a major institutional investor has slightly reduced its position, which might warrant a closer look at Regeneron's recent performance or upcoming catalysts, but it's not a strong sell signal.

Key Numbers

5,194,729 — Shares Beneficially Owned (The total number of Regeneron shares Capital World Investors can control.)
4.7% — Percentage of Class (The proportion of Regeneron's common stock owned by Capital World Investors as of December 29, 2023.)
5,176,828 — Sole Voting Power (The number of shares Capital World Investors has the sole right to vote.)

Key Players & Entities

Capital World Investors (company) — the reporting person and institutional investor
Regeneron Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
5,194,729 (dollar_amount) — shares beneficially owned by Capital World Investors
4.7% (dollar_amount) — percentage of Regeneron's common stock owned by Capital World Investors
December 29, 2023 (date) — the date of the event requiring the filing
February 9, 2024 (date) — the filing date of the SC 13G/A amendment

Forward-Looking Statements

Capital World Investors will maintain a significant, but slightly reduced, stake in Regeneron Pharmaceuticals for the foreseeable future. (Capital World Investors) — medium confidence, target: December 29, 2024

FAQ

What is the primary purpose of this SC 13G/A filing?

This SC 13G/A filing is an amendment (Amendment No. 5) by Capital World Investors to update their beneficial ownership of Regeneron Pharmaceuticals, Inc. common stock, as required by Rule 13d-1(b) of the Securities Exchange Act of 1934.

Who is the reporting person in this filing, and what is their IRS Identification Number?

The reporting person is Capital World Investors, and their IRS Identification Number is 95-1411037, as stated on the cover page of the filing.

What was the 'Date of Event Which Requires Filing of this Statement'?

The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023, as specified on the cover page of the Schedule 13G.

How many shares of Regeneron Pharmaceuticals, Inc. common stock does Capital World Investors beneficially own, and what percentage does this represent?

Capital World Investors beneficially owns 5,194,729 shares of Regeneron Pharmaceuticals, Inc. common stock, which represents 4.7% of the class, according to items 9 and 13 on the cover page.

Does Capital World Investors have shared voting or dispositive power over any of these shares?

No, the filing indicates that Capital World Investors has '0' shared voting power (Item 6) and '0' shared dispositive power (Item 8) over the shares, meaning they exercise these powers solely.

From the Filing

0001422848-24-000245.txt : 20240209 0001422848-24-000245.hdr.sgml : 20240209 20240209181903 ACCESSION NUMBER: 0001422848-24-000245 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 24616791 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Capital World Investors CENTRAL INDEX KEY: 0001422849 ORGANIZATION NAME: IRS NUMBER: 951411037 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 BUSINESS PHONE: 213-486-9200 MAIL ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 ) * Regeneron Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75886F107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 75886F107 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 5,176,828 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 5,194,729 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,194,729 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.8% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Regeneron Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 777 Old Saw Mill River Road, Tarrytown, NY 10591 Item 2. (a) Name of Person Filing Capital World Investors (b) Address of Principal Business Office or, if None, Residence 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 75886F107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6